EMA vows to battle AbbVie in courts for full data transparency

AbbVie ($ABBV) and InterMune ($ITMN) may have won at least a temporary reprieve in their fight to stop the EMA from releasing trial data on their drugs. But the powerful agency is vowing to battle it out in court as they insist that the pharma industry will benefit from a big dose of transparency. "If the court decides we have to stop the release of data, I think that would be the worst possible boomerang for the industry," EMA Executive Director Guido Rasi told Reuters in an interview. "The most powerful weapon we have to tackle distrust is transparency. Story

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.